Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors

The incidence of severe immune-related adverse events (irAEs) in cancer subjects receiving immune checkpoint inhibitors (ICIs) following COVID-19 vaccination and the relationship between the incidence of severe irAE and the interval between COVID-19 vaccination and ICI dose have not been established...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Danielle Gilbert, Junxiao Hu, Theresa Medina, Elizabeth R. Kessler, Elaine T. Lam
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Taylor & Francis Group 2023-01-01
Saila:	Human Vaccines & Immunotherapeutics
Gaiak:	covid-19 vaccines immunotherapy checkpoint inhibitors cancer
Sarrera elektronikoa:	http://dx.doi.org/10.1080/21645515.2023.2207438
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!